Annual report pursuant to Section 13 and 15(d)

Related Party Transactions (Details Textual)

v2.4.0.8
Related Party Transactions (Details Textual) (USD $)
1 Months Ended 12 Months Ended 101 Months Ended 12 Months Ended 101 Months Ended 12 Months Ended 101 Months Ended 12 Months Ended
Feb. 28, 2011
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
Feb. 18, 2011
Dec. 31, 2013
Exercise Price One [Member]
Dec. 31, 2013
Exercise Price Two [Member]
Dec. 31, 2013
Consulting Arrangements [Member]
Dec. 31, 2012
Consulting Arrangements [Member]
Dec. 31, 2013
Consulting Arrangements [Member]
May 31, 2013
Consulting Arrangements [Member]
Dec. 01, 2012
Consulting Arrangements [Member]
May 21, 2012
Consulting Arrangements [Member]
Oct. 15, 2011
Consulting Arrangements [Member]
Apr. 15, 2011
Consulting Arrangements [Member]
Feb. 18, 2011
Consulting Arrangements [Member]
Oct. 15, 2010
Consulting Arrangements [Member]
Apr. 15, 2010
Consulting Arrangements [Member]
Apr. 07, 2010
Consulting Arrangements [Member]
Dec. 31, 2013
Consulting Arrangements [Member]
Dr. Von Hoff [Member]
Dec. 31, 2013
Agreement With Theradex Systems [Member]
Dec. 31, 2012
Agreement With Theradex Systems [Member]
Dec. 31, 2013
Agreement With Theradex Systems [Member]
Sep. 21, 2012
Agreement With Theradex Systems [Member]
Dec. 31, 2013
NDA Consulting Corp [Member]
Dec. 31, 2013
NDA Consulting Corp [Member]
June 24, 2014 [Member]
Dec. 31, 2013
NDA Consulting Corp [Member]
June 24, 2015 [Member]
Dec. 31, 2013
NDA Consulting Corp [Member]
June 24, 2016 [Member]
Dec. 31, 2013
NDA Consulting Corp [Member]
June 24, 2017 [Member]
Dec. 31, 2013
NDA Consulting Corp [Member]
June 24, Thereafter [Member]
Jan. 28, 2014
Subsequent Event [Member]
Exercise Price One [Member]
Jan. 28, 2014
Subsequent Event [Member]
Exercise Price Two [Member]
Related Party Transaction [Line Items]                                                                
Due to stockholder   $ 92,717 $ 92,717 $ 92,717                                                        
Officers Compensation, Approved, Per Month         5,000                                                      
Officers Compensation, Approved, Per Month, Effective Date Of Adoption Mar. 15, 2011                                                              
Officers' Compensation   60,000 60,000 167,500                                                        
Annual Fee Payable, Clinical Trial                                     25,000         2,000,000                
Annual Fee Payable, Clinical Trial, Installment Amount                       12,500 12,500 12,500 12,500   12,500 12,500                            
Consultancy Fees Paid               10,417 21,875 75,000                   4,000                        
Fees For Services Total   14,964 163,661                                   14,964 163,661 194,551                  
Stock Based Compensation Expense Relating To Directors Officers And Other Related Parties   119,250 1,017,004 3,598,461                                                        
Clinical Cost Charged To Operations Total                                         278,721                      
Additional Annual Fee Payable Clinical Trial                     25,000         25,000                                
Warrants Expired, Weighted Average Exercise Price   $ 0 $ 0.844     $ 0.50 $ 0.75                                                  
Warrants Exercisable   6,659,840 6,659,840 6,659,840   2,084,840 4,575,000                                               2,253,800 4,575,000
Stock Granted, Value, Share-based Compensation, Net of Forfeitures, Total                                                 $ 100,000              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number                                                   25,000 25,000 25,000 25,000 25,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price                                                 $ 0.13              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term                                                 5 years